Low frequency of E-cadherin alterations in familial breast cancer

被引:33
作者
Salahshor, S
Lei, HX
Huo, HG
Kristensen, VN
Loman, N
Sjöberg-Margolin, S
Borg, Å
Borresen-Dale, AL
Vorechovsky, I
Lindblom, A
机构
[1] Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Novum, Dept Biosci, Stockholm, Sweden
[3] Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway
[4] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden
来源
BREAST CANCER RESEARCH | 2001年 / 3卷 / 03期
关键词
breast cancer; ductal comedo-type; E-cadherin; familial; lobular;
D O I
10.1186/bcr295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to explore the possible role of E-cadherin in familial cancer, 19 familial breast cancer patients, whose tumours demonstrated loss of heterozygosity (LOH) at the E-cadherin locus, were screened for germline mutations. No pathogenic germline alterations were detected in these individuals. However, a somatic mutation was found (49-2A-->C) in one of the tumours. This tumour showed a pattern of both ductal and lobular histology. Another 10 families with cases of breast, gastric and colon cancer were also screened for germline mutations, and no mutations were found. A missense mutation in exon 12 of E-cadherin (1774G-->A; Ala592Thr) was previously found in one family with diffuse gastric cancer, and colon and breast cancer. An allelic association study was performed to determine whether the Ala592Thr alteration predisposes to breast cancer. In total, we studied 484 familial breast cancer patients, 614 sporadic breast cancer patients and 497 control individuals. The frequencies of this alteration were similar in these groups. However, a correlation between the Ala592Thr alteration and ductal comedo-type tumour was seen. These results, together with previously reported studies, indicate that germline mutations and, more commonly, somatic mutations in E-cadherin may have an influence on the behaviour of the tumours, rather than predispose to breast cancer.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 49 条
[1]   BRCA1 screening in patients with a family history of breast or ovarian cancer [J].
Arver, B ;
Claro, A ;
Langerod, A ;
Borresen-Dale, AL ;
Lindblom, A .
GENETIC TESTING, 1999, 3 (02) :223-226
[2]  
Becker K F, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU14>3.0.CO
[3]  
2-Z
[4]   EXON SKIPPING IN THE E-CADHERIN GENE TRANSCRIPT IN METASTATIC HUMAN GASTRIC CARCINOMAS [J].
BECKER, KF ;
ATKINSON, MJ ;
REICH, U ;
HUANG, HH ;
NEKARDA, H ;
SIEWERT, JR ;
HOFLER, H .
HUMAN MOLECULAR GENETICS, 1993, 2 (06) :803-804
[5]  
BECKER KF, 1994, CANCER RES, V54, P3845
[6]  
Berx G, 1996, ONCOGENE, V13, P1919
[7]   E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers [J].
Berx, G ;
CletonJansen, AM ;
Nollet, F ;
deLeeuw, WJF ;
vandeVijver, MJ ;
Cornelisse, C ;
vanRoy, F .
EMBO JOURNAL, 1995, 14 (24) :6107-6115
[8]  
Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO
[9]  
2-Y
[10]  
Caligo MA, 1998, INT J ONCOL, V13, P177